Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
Type:
Grant
Filed:
October 28, 1996
Date of Patent:
February 17, 1998
Assignee:
Merck & Co., Inc.
Inventors:
John J. Acton, III, Alan D. Adams, Jeffrey D. Hermes, A. Brian Jones, William Hugh Parsons, Peter J. Sinclair